Skip to main content
News Icon

News categories: Publication

Possible SARS-CoV-2 mass testing with new technology

Prof. Dr. Jonathan Schmid-Burgk heads the new working group for "Functional Immunogenomics" at the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn. As part of the newly established professorship and management position, the 34-year-old genome researcher is investigating the complex interplay between genes and our immune system. With the help of robotics and artificial intelligence (AI), he is developing new techniques for protein analysis in living human cells with programmable gene scissors. The aim is to accelerate the modification of the human genome in order to analyze it. Prof. Schmid-Burgk is currently working on a mass test for COVID-19 using the LAMP-Seq process he developed. He brings his new techniques to the Cluster of Excellence ImmunoSensation at the University of Bonn. Following his doctorate, for which he received the doctoral award from the Bonn University Society in 2017, his previous academic career led Prof. Schmid-Burgk to Cambridge (USA). There he spent three and a half years researching at the Broad Institute of MIT and Harvard - funded by a grant from the European Molecular Biology Organization (EMBO).

Related news

News Icon

News categories: Publication

New vulnerability of asthma immune cells discovered

Why do certain immune cells remain permanently active in allergic asthma – even in an environment that should actually damage them? A team from the University Hospital Bonn (UKB) and the University of Bonn has discovered that these cells only survive because they activate a special antioxidant protection mechanism. When this mechanism is blocked, allergic inflammation in mouse models decreases significantly. The results have now been published in the scientific journal Immunity.
View entry
The human P2X4 receptor

News categories: Publication

A starting point for the development of new pain and cancer drugs

The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry
Kato research group

News categories: Publication

Ominous false alarm in the kidney

Bonn researchers have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.
View entry

Back to the news overview